The complete sequencing of the human genome is one of the most powerful examples of technology and science in action: We've gone from needing $3 billion and over 13 years to read a single human genome to today, to where we can do that same amount of work for about $1,000 in roughly 2 days -- and the price will only continue to drop. But beyond pricing, what does understanding the gene -- and moving from the sequencing layer to the applications layer -- mean to us; what new questions arise now that we can sequence DNA quickly, reliably, and cheaply?

This conversation -- with co-founder and CEO of Jungla Carlos Araya and co-founder and CEO of Freenome Gabe Otte, moderated by a16z General Partner Jorge Conde (based on a discussion that took place at a16z’s annual Summit in November 2017) -- takes a step back and considers all these questions. Every time a human genome sequence is completed, there are on the order of 3,000,000 new variants identified. So how do we think about interpreting all that data? Actionability? And how do we derive meaning from all this, for applications in the clinical space?

–––

The views expressed here are those of the individual AH Capital Management, L.L.C. (“a16z”) personnel quoted and are not the views of a16z or its affiliates. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation.

This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. You should consult your own advisers as to those matters. References to any securities or digital assets are for illustrative purposes only, and do not constitute an investment recommendation or offer to provide investment advisory services. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. (An offering to invest in an a16z fund will be made only by the private placement memorandum, subscription agreement, and other relevant documentation of any such fund and should be read in their entirety.) Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z, and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by Andreessen Horowitz (excluding investments and certain publicly traded cryptocurrencies/ digital assets for which the issuer has not provided permission for a16z to disclose publicly) is available at https://a16z.com/investments/.

Charts and graphs provided within are for informational purposes solely and should not be relied upon when making any investment decision. Past performance is not indicative of future results. The content speaks only as of the date indicated. Any projections, estimates, forecasts, targets, prospects, and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Please see https://a16z.com/disclosures for additional important information.

a16z Podcast: Revisiting the Gene

The a16z Show